Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001239107 | SCV001411957 | uncertain significance | Hereditary spastic paraplegia 49 | 2022-08-23 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with histidine, which is basic and polar, at codon 273 of the TECPR2 protein (p.Arg273His). This variant is present in population databases (rs144069125, gnomAD 0.03%). This variant has not been reported in the literature in individuals affected with TECPR2-related conditions. ClinVar contains an entry for this variant (Variation ID: 964805). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Baylor Genetics | RCV001239107 | SCV001522279 | uncertain significance | Hereditary spastic paraplegia 49 | 2020-05-05 | criteria provided, single submitter | clinical testing | This variant was determined to be of uncertain significance according to ACMG Guidelines, 2015 [PMID:25741868]. |
Genome Diagnostics Laboratory, |
RCV001847203 | SCV002105970 | uncertain significance | Hereditary spastic paraplegia | 2019-05-01 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV001239107 | SCV002780954 | uncertain significance | Hereditary spastic paraplegia 49 | 2021-07-15 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002563934 | SCV003709282 | uncertain significance | Inborn genetic diseases | 2021-07-14 | criteria provided, single submitter | clinical testing | The c.818G>A (p.R273H) alteration is located in exon 6 (coding exon 5) of the TECPR2 gene. This alteration results from a G to A substitution at nucleotide position 818, causing the arginine (R) at amino acid position 273 to be replaced by a histidine (H). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Breakthrough Genomics, |
RCV004692284 | SCV005194285 | uncertain significance | not provided | criteria provided, single submitter | not provided | ||
Natera, |
RCV001239107 | SCV002087998 | uncertain significance | Hereditary spastic paraplegia 49 | 2019-12-09 | no assertion criteria provided | clinical testing |